Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Active Trials
    0(0%)

    Phase Distribution

    Phase 2
    1
    100%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    0

    Late Stage

    Phase Distribution1 total trials
    Phase 2Efficacy & side effects
    1(100.0%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 1 finished

    Non-Completion Rate

    100.0%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    1

    all time

    Status Distribution
    Terminated(1)

    Detailed Status

    Withdrawn1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    1
    Active
    0
    Success Rate
    N/A
    Most Advanced
    Phase 2

    Trials by Phase

    Phase 21 (100.0%)

    Trials by Status

    withdrawn1100%

    Recent Activity

    0 active trials
    Showing 1 of 1
    withdrawnphase_2

    Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients

    NCT05504642

    Clinical Trials (1)

    Showing 1 of 1 trials
    NCT05504642Phase 2

    Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients

    Withdrawn

    All 1 trials loaded

    Drug Details

    Intervention Type
    Procedure
    Total Trials
    1